This podcast was supported by GSK who were not involved in its creation or development.
In this episode of ‘Beyond Response: Understanding dMMR/MSI-H Outcomes in Gastrointestinal Immunotherapy’, host Sue Saville is joined by Campbell Roxburgh, Jenny Seligmann, and Damian Tolan to discuss how response to immunotherapy is assessed in dMMR/MSI-H gastrointestinal cancers. The panel brings together surgical, oncology, and radiology perspectives on how different response definitions can inform downstream treatment decisions.
Topics Covered:
- The importance of pathological complete response for patient outcomes
- How radiologic response is determined and adapted for immunotherapy, including iRECIST, RECIST 1.1, and pseudoprogression
- Early response and clinical complete response as indicators of outcome
- How response information is incorporated into surgical decision making
- Differences between investigator-assessed response and independent central review in trials
Moderator:
Sue Saville
Independent Healthcare Communications Specialist
Speakers:
Campbell Roxburgh1
Jenny Seligmann2
Damian Tolan3
- Consultant Colorectal Surgeon and Professor of Colorectal Surgical Oncology, University of Glasgow, UK
- Professor of Gastrointestinal and Translational Oncology, Leeds Teaching Hospitals NHS Trust; Consultant in Medical Oncology, University of Leeds, UK
- Consultant Gastrointestinal Radiologist, St James’s University Hospital, Leeds, UK
